EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer

Eva Welsch iD, Lilli Bonstingl iD, Barbara Holzer, Eva Schuster, Esther Weiß iD, Alexandru-Teodor Zaharie iD, Michael Krainer iD, Michael B Fischer iD, Amin El-Heliebi iD, Robert Zeillinger iD, Eva Obermayr iD

Clinical & Experimental Metastasis · 2024

DOI: 10.1007/s10585-024-10313-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Metastasis, 2024. Verfasst von Eva Welsch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-2…. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor cells (CTCs) are an established prognostic marker in metastatic prostate cancer (PrC) but have received little attention in localized high-risk disease. Peripheral blood was obtained from patients with early intermediate and high-risk PrC ( n = 15) at baseline, after radiotherapy, and during follow-up, as well as from metastatic PrC patients ( n = 23). CTCs were enriched using the microfluidic Parsortix ® technology. CTC-related marker were quantified with qPCR and RNA in-situ hybridization (ISH). Positivity and associations to clinical parameters were assessed using McNemar test, Fisher Exact test or log-rank test. The overall positivity was high in both cohorts (87.0% metastatic vs. 66.7% early at baseline). A high concordance of qPCR and RNA ISH was achieved. In metastatic PrC, PSA and PSMA were prognostic for shorter overall survival. In early PrC patients, an increase of positive transcripts per blood sample was observed from before to after radiation therapy, while a decrease of positive markers was observed during follow-up. CTC analysis using the investigated qPCR marker panel serves as tool for achieving high detection rates of PrC patient samples even in localized disease. RNA ISH offers the advantage of confirming these markers at the single cell level. Employing the clinically relevant marker PSMA, our CTC approach can be used for diagnostic purposes to screen patients profiting from PSMA-directed PET-CT or PSMA-targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingProstatic NeoplasmsBiomarkers, TumorHumansMaleAgedPrognosisMiddle AgedProstate-Specific AntigenGlutamate Carboxypeptidase IIIn Situ HybridizationNeoplasm MetastasisAged, 80 and overFollow-Up StudiesAntigens, Surface

Stichwörter der Autor:innen

Circulating tumor cellsGene expressionLiquid biopsyParsortixProstate cancerqPCR

Substanzen

Biomarkers, TumorProstate-Specific AntigenGlutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria.
  • Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Centre, Medical University of Graz, Graz, Austria.
  • European Liquid Biopsy Society (ELBS), Hamburg, Germany.
  • OncoLab Diagnostics GmbH, Wiener Neustadt, Austria.
  • Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
  • Division of Oncology, Department for Medicine I, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Eva Welsch, Lilli Bonstingl, Esther Weiß, Alexandru-Teodor Zaharie, Michael Krainer, Michael B Fischer, Amin El-Heliebi, Robert Zeillinger, Eva Obermayr

Förderung

  • Medical University of Vienna

Zitieren

APA

Welsch, E., Bonstingl, L., Holzer, B., Schuster, E., Weiß, E., Zaharie, A. T., Krainer, M., Fischer, M. B., El-Heliebi, A., Zeillinger, R., & Obermayr, E. (2024). Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-024-10313-2

Vancouver

Welsch E, Bonstingl L, Holzer B, Schuster E, Weiß E, Zaharie AT, et al. Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer. Clinical & Experimental Metastasis. 2024. doi:10.1007/s10585-024-10313-2

BibTeX
@article{Welsch2024,
  author = {Welsch, Eva and Bonstingl, Lilli and Holzer, Barbara and Schuster, Eva and Weiß, Esther and Zaharie, Alexandru-Teodor and Krainer, Michael and Fischer, Michael B and El-Heliebi, Amin and Zeillinger, Robert and Obermayr, Eva},
  title = {Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer},
  journal = {Clinical & Experimental Metastasis},
  year = {2024},
  doi = {10.1007/s10585-024-10313-2}
}
Kostenlos starten →